Medpage Today: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial.

The cardiac myosin inhibitor improved Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score by 9.1 points more than that seen with placebo over 30 weeks (mean 14.9 vs 5.4 points, P<0.001 for difference). A 5-point change in score is considered clinically significant.

Similar advantages were seen across all KCCQ subscores, reported John Spertus, MD, MPH, of Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, at the virtual American College of Cardiology meeting and simultaneously in The Lancet.

Read the full Medpage Today article: Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Related Content

May. 19, 2021

EXPLORER-HCM Trial shows dramatic improvements in patients with common genetic heart condition, comes after decades of no new treatments
Saint Luke’s Mid America Heart Institute announced the results of a clinical trial that will impact patient care and improve quality of life for patients suffering from the most common genetic heart condition.
May. 17, 2021

Healio: Marked health status improvement with mavacamten in obstructive hypertrophic cardiomyopathy
Dr. John Spertus presented new health status data from the EXPLORER-HCM Trial at the ACC Scientific Session.
May. 14, 2021

Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.